AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $17M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$17M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 1 cutEven
Key stats
Fundamentals Sep 30- Open
- $38.90
- 52-wk high
- $40.79
- High
- $40.24
- 52-wk low
- $18.83
- Low
- $38.67
- Prev close
- $39.81
- Mkt cap
- $46.43B
- P/E
- 65.3x
- Volume
- 6.69M
- Fwd P/E
- 7.0x
- Beta
- 0.80
- P/S
- 2.7x
- P/B
- 3.4x
- Profit margin
- +4.1%
- Op margin
- +4.0%
- ROE
- +9.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TEVA filings
Are insiders buying or selling Teva Pharma Industries Ltd ADR (TEVA) stock?
Net selling: insiders sold $17M and bought $0 of TEVA stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $2M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Mignone, Roberto (Director), who sold $14.4M. The latest filing was on Sep 22, 2026.
Which members of Congress have traded TEVA recently?
None. No member of Congress disclosed a TEVA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TEVA smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- MI
Millennium
$53.6M
added
Sells/Trims (2)
- SD
Stanley Druckenmiller
$50.4M
trimmed
- GC
Glenview Capital
$321.2M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in TEVA right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in $0.59 a share above what analysts expected.
Earnings per share
$0.05 expected
Reports Nov 3, 2026, in 33 days
Estimates as of Sep 30, 2026
EPS expected
$0.60 to $0.77
Revenue expected
10 analysts
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.48B | $4.71B | $3.98B | $4.14B |
| Cost of what it sold | $2.18B | $2.06B | $2.01B | $1.99B |
| Gross profit | $2.30B | $2.66B | $1.97B | $2.15B |
| What it spent | ||||
| Research and development | $256.0M | $267.0M | $222.0M | $250.0M |
| Sales and admin | $317.0M | $367.0M | $304.0M | $317.0M |
| Other operating costs | $849.0M | $1.72B | $792.0M | $1.44B |
| Total operating expenses | $1.42B | $2.35B | $1.32B | $2.00B |
| What was left | ||||
| Operating profit | $882.0M | $300.0M | $652.0M | $149.0M |
| Interest on debt | $209.0M | $292.0M | $201.0M | $200.0M |
| Profit before tax | $648.0M | $91.0M | $436.0M | -$455.0M |
| Tax | $214.0M | -$390.0M | $67.0M | $121.0M |
| Net profit | $433.0M | $480.0M | $369.0M | -$576.0M |
| EBITDA | $1.10B | $632.0M | $877.0M | -$19.0M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
BullishSep 29Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications
BullishSep 29Teva Pharmaceutical Industries Gains FDA Nod for Degevma Biosimi
NeutralSep 28Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds
BullishSep 25Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug
NeutralSep 25Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
NeutralSep 24Director’s fund exits Teva Pharmaceutical Industries (TEVA) stake in one-day sale
BearishSep 23Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock
NeutralSep 22
Macro
33 macro signals shaping TEVA right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results